Comparison of efficacy of intralesional meglumine antimoniate vs. combination of 50% trichloroacetic acid and intralesional meglumine antimoniate in patients of cutaneous leishmaniasis

Quratulain Ejaz, Nighat Akbar, Sumyra Saleem

Abstract


Objective is an endemic disease. This study was done to compare the efficacy of intralesional meglumine antimoniate (MA) with combination of 50% trichloroacetic acid (TCA) and intralesional meglumine antimoniate in patients of cutaneous leishmaniasis (CL).

 

Methods It was a randomized controlled trial conducted in department of dermatology, Military Hospital, Rawalpindi over six months i.e. 02-08-2016 to 01-02-2017. A total of 210 patients (105 in each group) were taken in this study. Group A received 50% TCA fortnightly with intralesional meglumine antimoniate and group B was treated with intralesional meglumine antimoniate alone.

 

Results Efficacy was observed in 91 (86.7%) patients of group A and in 78 (74.3%) patients of group B (p=0.024).

 

Conclusion Combination therapy with TCA 50% and intralesional MA accelerated the resolution of CL lesions with significant difference in complete resolution rate in comparison to the patients treated with intralesional MA alone.

 


Keywords


Cutaneous leishmaniasis, intralesional injection, meglumine antimoniate, trichloroacetic acid, topical therapy

Full Text:

PDF

References


Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. J Infect Public Health. 2013;6:120-4.

Afghan AL, Kassi M, Kasi PM, Ayub A, Kakar N, Marri SM. Clinical manifestations and distribution of cutaneous leishmaniasis in Pakistan. J Trop Med. 2011;2011:359145.

Nilforoushzadeh MA, Jaffary F, Derakhshan R, Haftbaradaran E. Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis: a randomized clinical trial. J Skin Stem Cell. 2014;1:e16633.

Ali NM, Fariba J, Elaheh H, Ali N. The efficacy of 5% trichloroacetic acid cream in the treatment of cutaneous leishmaniasis lesions. J Dermatolog Treat. 2012;23:136-9.

Banihashemi M, Yazdanpanah MJ, Amirsolymani H, Yousefzadeh H. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic acid and intralesional meglumine antimoniate. J Cutan Med Surg. 2015;19:35-9.

Silva RE, Toledo A Júnior, Senna MC, Rabello A, Cota G. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. Mem Inst Oswaldo Cruz. 2016;111:512-6.

Khan SJ, Muneeb S. Cutaneous leishmaniasis in Pakistan. Dermatol Online J. 2005;11:1-4.

Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.

González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2008;4:CD005067.

Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53:158-66.

World Health Organization. The leishmaniases. WHO technical report series, vol. 701. Geneva: WHO; 1984.

Garrett SJ, Robinson JK, Roenigk HH Jr. Trichloroacetic acid peel of molluscum contagiosum in immunocompromised patients. J Dermatol Surg Oncol. 1992;18:855-8.

El-Domyati MB, Attia SK, Saleh FY, Ahmad HM, Uitto JJ. Trichloroacetic acid peeling versus dermabrasion: a histometric, immunohistochemical, and ultrastructural comparison. Dermatol Surg. 2004;30:179-88.

Yug A, Lane JE, Howard MS, Kent DE. Histologic study of depressed acne scars treated with serial high-concentration (95%) trichloroacetic acid. Dermatol Surg. 2006;32:985-90.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014